Advertisement
Canada markets close in 3 hours 24 minutes
  • S&P/TSX

    22,168.69
    +61.61 (+0.28%)
     
  • S&P 500

    5,251.22
    +2.73 (+0.05%)
     
  • DOW

    39,761.12
    +1.04 (+0.00%)
     
  • CAD/USD

    0.7389
    +0.0016 (+0.22%)
     
  • CRUDE OIL

    82.66
    +1.31 (+1.61%)
     
  • Bitcoin CAD

    96,034.97
    +2,526.84 (+2.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,237.80
    +25.10 (+1.13%)
     
  • RUSSELL 2000

    2,133.42
    +19.07 (+0.90%)
     
  • 10-Yr Bond

    4.1890
    -0.0070 (-0.17%)
     
  • NASDAQ

    16,385.96
    -13.56 (-0.08%)
     
  • VOLATILITY

    12.92
    +0.14 (+1.10%)
     
  • FTSE

    7,961.13
    +29.15 (+0.37%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6838
    +0.0033 (+0.48%)
     

STOCKHOLDER ALERT: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Acquisition

NEW YORK, NY / ACCESSWIRE / December 10, 2019 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

  • Instructure, Inc (INST) related to its sale to PIV Purchaser, LLC. Under the terms of the Merger, each share of Instructure common stock will automatically be converted into the right to receive $47.60 in cash for each share of Instructure common stock owned. Click here for more information: https://www.monteverdelaw.com/case/instructure-inc. It is free and there is no cost or obligation to you.

  • Audentes Therapeutics, Inc (BOLD) related to its sale to Astellas Pharma, Inc. Under the terms of the Agreement, Audentes shareholders will have the right to receive $60.00 in cash for each Audentes common stock owned. Click here for more information: https://www.monteverdelaw.com/case/audentes-therapeutics-inc. It is free and there is no cost or obligation to you.

  • TD Ameritrade Holding Corporation (AMTD) ("Ameritrade") related to its sale to The Charles Schwab Corporation ("Schwab"). Under the terms of the Merger, Ameritrade common stock will be converted into the right to receive 1.0837 shares of Schwab voting common stock for each Ameritrade common stock owned. Click here for more information: https://www.monteverdelaw.com/case/td-ameritrade-holding-corporation. It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019 an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.

ADVERTISEMENT

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

CONTACT:

Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2019 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE: Monteverde & Associates PC



View source version on accesswire.com:
https://www.accesswire.com/569793/STOCKHOLDER-ALERT-Monteverde-Associates-PC-Continues-its-Legal-Inquiry-for-the-Recent-Acquisition